New paper in Frontiers in Medicine reveals first reliable biomarker test for early kidney transplant rejection detection in living-donor recipients
- Use of numares’ metabolite constellation showed a stable urinary metabolic profile in the first 14 days for living donor recipients, enabling accurate early rejection detection
- Deceased donor recipients exhibit ischemia‑driven metabolic alterations that transiently mask rejection signals
- Groundbreaking study was led by researchers at University Hospital Regensburg in conjunction with numares Health
Regensburg, Germany, 09 March 2026 – numares Health (“numares”), the transformative metabolomics company pioneering multidimensional biomarker insights that deliver clinical pathways for optimal patient care, today announces the publication of a new analysis in Frontiers in Medicine highlighting numares’ urinary metabolite constellation as the first biomarker test to show reliable diagnostic accuracy for detecting acute kidney transplant rejection during the critical first 14 days after transplantation in recipients of living donor kidneys.
